QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Inclusion Criteria: * 1\. Subjects participate voluntarily and sign informed consent. * 2\. Age ≥ 18 and ≤ 80 years old, male or female. * 3\. Histologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the colon or rectum. * 4\. At least 1 measurable target lesion according to Response Evaluation in Solid Tumors (RECIST 1.1). Exclusion Criteria: * 1\. Diagnosed additional maliganancy within 5 years with the expection of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin,curatively resected in situ cervival or non-muscle invasive bladder cancers. * 2\. Presence of brain metastases (asymptomatic brain metastases or symptomatic brain metastases who are stable at least 4 weeks, were allowed to be enrolled). * 3\. Has active autoimmune disease that has required systemic treatment in past 2 years. * 4\. Significant cardiovascular disease.